◆ NeutralABTJNJISRG
Abbott: 3 Key Takeaways for Long-Term Investors
The Motley Fool·
Abbott announced plans to spin off its nutrition business into an independent public company, focusing on higher-margin medical technologies and diagnostics. The company reported 7% year-over-year comparable sales growth in Q3 2026, with cancer diagnostics sales up 14% driven by Cologuard and new blood-based colorectal cancer screening tests. Pulsed field ablation technology is accelerating growth in electrophysiology, positioning Abbott for accelerated growth beyond historical rates.
Read Full Article at The Motley Fool →